VIARTIS
|
||
|
PARKINSON'S DISEASE NEWS
|
|
25th August 2011 - New research DOPAMINE AGONISTS INCREASE THE RISK OF VALVULAR REGURGITATION Movement Disorders [2011] 26 (5) : 801-806 (V.G.Rasmussen, K.Østergaard, E.Dupont, S.H.Poulsen) Complete abstract The use of dopamine agonists increases the risk of valvular regurgitation in people with Parkinson's Disease. Valvular regurgitation is when a cardiac valve becomes diseased or damaged, and is no longer able to close properly. Leakage of blood occurs across the valve. This leakage of blood is referred to as regurgitation. Valvular regurgitation can lead to abnormal cardiac function. For more information go to Mitral valvular regurgitation. Cabergoline, which is also known by the brand names Dostinex and Cabaser, was the worst of those dopamine agonists assessed. The likelihood of valvular regurgitation in people with Parkinson's Disease taking Cabergoline was more than six times greater than would otherwise be expected. For a full review of Cabergoline go to the Review of Cabergoline. The dopamine agonist Pergolide, which is also known as Permax, makes valvular regurgitation in people with Parkinson's Disease more than three times more likely. The likelihood of Permax causing valvular regurgitation led to its withdrawal in the U.S. in 2007, but it is still used elsewhere. Other dopamine agonists were not assessed. So it is not known to what extent they are harmful in this respect or if they are harmful at all. For more current news go to Parkinson's Disease News.E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail [email protected] with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.
Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided, as well as links to the complete abstracts and news reports
|
||
|
||
©2006-2011 Viartis | ||
2015-09-06 12:58:10 | ||
[email protected] |